Thursday, December 21, 2023 10:12:07 AM
https://www.marketscreener.com/quote/stock/DYADIC-INTERNATIONAL-INC-57599342/news/Dyadic-International-Inc-NASDAQ-DYAI-Advances-Biopharmaceutical-Innovations-and-Vaccine-Manufac-45617311/
Dyadic International Inc. (NASDAQ: DYAI), a leading biotechnology firm, focuses on developing innovative microbial platforms to address the increasing global demand for protein bioproduction. Furthermore, the company aims to fulfil unmet clinical and industrial needs by providing cost-effective, accessible, and efficient biopharmaceutical products for both human and animal applications.
Operating from the United States, this company has achieved success in developing a gene expression platform designed for the commercial synthesis of enzymes and various proteins. Utilizing this platform through licensing agreements, the company has leased it to Codexis, Inc. (NASDAQ: CDXS), BASF SE (OTCQX: BASFY, BASF.DE), Abengoa Bioenergy (OTC: AGOAF), and others in the past. In the past two years, the company has constructed another platform named Dapibus(TM), specifically designed to facilitate the production of metabolites, proteins, and other biological products for non-pharmaceutical applications.
Recently, Rubic One Health, the African licensee of Dyadic International, entered into an agreement with Afreximbank to secure funding for a vaccine manufacturing project facility. The vaccines will be produced utilizing Dyadic's C1 protein production platform, and manufacturing operations will take place in South Africa, with distribution planned across the entire continent.
Devoted to assisting its collaborators and partners in creating impactful therapeutic and preventive treatments, the company extends its support to partners in both developed and emerging nations. Dyadic International is actively advancing its microbial platform technologies, which encompass DYAI-100, its candidate for a COVID-19 vaccine. Concurrently, the company is engaged in the progression of additional biologic candidates and vaccines.
On November 20, a significant milestone occurred following the company's disclosure of a partnership agreement signed by Rubic One Health, its African licensee. Dyadic International conveyed that Rubic One Health had entered into an agreement with Afreximbank to secure funding for the project preparation facility dedicated to vaccine manufacturing. The announcement highlighted that the vaccines would be produced utilizing Dyadic's C1 protein production platform, with manufacturing operations set to take place in South Africa and distribution planned across the entire continent.
Additionally, the company broadened its pre-existing licensing arrangement with South African-based Rubic One Health. Under the terms of this extended agreement, Rubic is set to utilize Dyadic International's C1 platform for the exploration, development, and cost-effective, high-quality manufacturing of vaccines, catering to both human and animal use. The expanded licensing agreement emphasizes the distribution of these vaccines primarily in the African market. The recognition of the imperative to produce vaccines in Africa became evident with the signing of this deal by Rubic One Health.
Dyadic International, Inc. (NASDAQ: DYAI) is trading above is 30-day and 60-day averages at $1.58 and is position below its 20, 50, and 200-day moving averages, with a 52-week peak at $2.40, suggesting consolidation and signaling a potential transition to an upward trajectory. Considering these indicators, DYAI is a stock that warrants close monitoring in the current period and in the coming weeks.
Recent DYAI News
- Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024 • GlobeNewswire Inc. • 04/30/2024 08:30:00 PM
- Dyadic Reports 2023 Full Year Results and Recent Company Progress • GlobeNewswire Inc. • 03/28/2024 08:00:00 PM
- Dyadic Announces Change in Board and Management Leadership Roles • GlobeNewswire Inc. • 03/28/2024 12:30:00 PM
- Dyadic to Attend Industry Events in April • GlobeNewswire Inc. • 03/27/2024 12:30:00 PM
- Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications • GlobeNewswire Inc. • 03/26/2024 12:30:00 PM
- Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California • GlobeNewswire Inc. • 03/21/2024 12:30:00 PM
- Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024 • GlobeNewswire Inc. • 03/14/2024 08:30:00 PM
- CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization • GlobeNewswire Inc. • 03/11/2024 01:57:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:45:28 PM
- Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization • GlobeNewswire Inc. • 03/11/2024 12:30:00 PM
- Dyadic to Attend Industry Events in March • GlobeNewswire Inc. • 03/01/2024 01:30:00 PM
- Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform • GlobeNewswire Inc. • 02/28/2024 01:30:00 PM
- Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions • GlobeNewswire Inc. • 02/21/2024 01:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:41:59 PM
- Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing • GlobeNewswire Inc. • 02/13/2024 01:30:00 PM
- Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company • GlobeNewswire Inc. • 02/06/2024 01:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/01/2024 09:15:18 PM
- Dyadic to Attend BIO CEO & Investor Conference and European Industry Events • GlobeNewswire Inc. • 02/01/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 01:07:52 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 01:07:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 01:05:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 01:05:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 01:04:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 01:03:24 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 01:02:40 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM